Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and immunological response following homologous or heterologous booster COVID-19 vaccination (3rd dose)
TCTR20210719006Phase 2Completed
- Sponsor
- Faculty of Medicine Siriraj Hospital, Mahidol University
- Start
- Dec 2021
- Countries
- 1
01
Overview
Phase 2 trial in coronavirus disease 2019 (COVID-19), sponsored by Faculty of Medicine Siriraj Hospital, Mahidol University. Primary endpoints: Safety of homologous and heterologous booster COVID-19 vaccination and Immunological response to homologous and heterologous booster COVID-19 vaccination. Started Dec 2021; status: completed.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20210719006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210719006.